|
|
 |
 |
|
Abstract Submission Deadline:
April 9, 2012, 11:59 PM, Central Time
|
|
To submit your abstract using the online submission form, you
will need:
|
|
| |
|
SUBMISSION RULES
Acceptance:
New this year: Some accepted abstracts will be selected for presentation in rapid fire oral abstract sessions. If your abstract is chosen for an oral presentation, the notification and details will be included with the abstract acceptance letter. Abstracts accepted for rapid fire oral presentation will also be featured posters on the same day as part of the poster session.
In addition a few accepted abstracts may be selected for presentation in an oral abstract session. If your abstract is chosen for this session, notification and details will be included with the abstract acceptance letter. Abstracts chosen for this session would be oral only, no poster presentation.
- Abstracts accepted are embargoed for release until the time of presentation
at the Heart Failure Society of America's Scientific Meeting; information
may not be released before then.
- Abstract grading is blinded. Abstracts are selected on the basis of
scientific merit.
- Acceptance notifications will be sent on or about May 24, 2012.
- Abstracts accepted for presentation will be published as a supplement
to the Journal of Cardiac Failure. Authors whose abstracts are accepted
give HFSA permission and the authority to submit and have published
his/her abstract, without compensation in the Journal of Cardiac Failure.
Authors will be expected to attend the meeting and present their
posters.
- All abstracts submitted must comply with the guidelines to be considered for acceptance.
- Withdrawal of accepted abstracts must be received in writing by HFSA no later than June 17, 2012 to avoid publication in the Journal of Cardiac Failure supplement.
Abstract Data:
- The Heart Failure Society of America is a forum for presentation of
novel research findings. Therefore, work covered by the abstract
must not have been published (manuscript or abstract), prior to
March 31, 2012.
- Abstract data may not be presented at a national meeting or world
congress in the United States prior to July 1, 2012.
- Authors should not "split" data to create several abstracts from one. If
splitting is judged to have occurred, scores of related abstracts will be
reduced.
- Abstracts containing identical or nearly identical data submitted from
the same institution and/or individuals will be disqualified.
- Informed consent: Any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1996;14:103) and must meet all of the requirements governing informed consent of the country in which the study was performed. Any procedures performed must meet with prevailing ethical standards.
- Use of Animals: All studies involving the use of animals must conform with the 1991 revision of “Guiding Principles in the Care and Use of Animals” (American Physiological Association).
- Briefly describe the objectives of the study unless they are contained in
the title. If applicable, include a brief statement of methods. State
findings in sufficient detail to support conclusions. Abstracts should not
describe research in which the chemical identity or source of the
reagent is proprietary or cannot be revealed.
- Use generic drug names only. Product based names are to be used only when necessary.
- Avoid beginning sentences with numerals.
- Standard abbreviations may be used without definition. Nonstandard
abbreviations (minimum number) should be placed in parentheses after
the first use of the word or phrase abbreviated.
- No references, credits or grant support should be included in
the abstract.
- No identifying information about patients participating in a study or trial
should be used (name or personal information).
- Check category for submission carefully to assure proper scientific
consideration.
- Proofread abstracts carefully to avoid errors before submission. No
corrections will be allowed once abstract has been submitted.
Industry Abstract Submissions:
Abstract submissions from industry representatives are allowed. Submissions are required to focus on science and research and not on specific products or services. Abstract presentation may NOT be sale presentations and/or endorsement for products or services.
Disclosures:
A disclosure form identifying commercial relationships for all co-authors
will need to be completed online for each abstract by the submitting
author. Disclosure information for accepted abstracts will be made
available to the 2012 scientific meeting attendees.
|
| Online Submission Notes |
| |
This section contains information to guide you through the online submission process. We recommend that you print this page and use it as a reference during this process.
- Click the buttons on the left side of the screen and complete each section. Be sure to carefully follow the instructions within each section.
- Save your work by clicking Save Information. This does not submit your abstract for review. Be sure to save your work before logging off the site.
- You can log off at any time without submitting your abstract and return to continue your work at another time. As long as you do not submit the abstract, it can be edited and revised online as many times as needed. If you give your username and password to another person, they will have access to edit all abstracts you have not submitted for review.
- Verify that your abstract is correct by clicking Preview Abstract.
- Click on Submit Your Abstract, but ONLY when you are sure that your abstract is complete and in final form.
- Print out and proofread the abstract preview to verify that it is correct before completing the submission process.
|
Heart Failure Society of America Abstracts
c/o Marathon Multimedia
1201 West Division Street
Faribault, MN 55021
Phone: Toll-free 1.866.759.5440 (Within the U.S.)*
Phone: 507.333.1000 (Outside the U.S.)*
*(8:00 AM - 5:00 PM Central Time USA, Monday - Friday).
Fax: 507.334.0014
|
Deadline: All abstracts must be submitted by
April 9, 2012, 11:59 PM, Central Time.
If not submitted by this date, your abstract will not be considered.
|
|